Investors should monitor upcoming topline data from the Phase 3 ARCHER II trial in Q4 2026, which could be a major value driver. The MAA filing in Europe for tanruprubart represents near-term regulatory risk/reward, while the planned 2026 U.S. BLA submission depends on FORWARD study outcomes.
Price Chart
Executive Summary
Annexon Biosciences reported fourth quarter and full year 2025 financial results, highlighting a strong cash position of $238.3 million and progress in its late-stage clinical programs for vonaprument (GA) and tanruprubart (GBS). The company expects topline Phase 3 data for vonaprument in Q4 2026 and plans a U.S. BLA submission for tanruprubart in 2026 based on FORWARD study data.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and short-term investments totaled $238.3 million as of December 31, 2025, providing runway into the second half of 2027.
- R&D expenses increased to $184.7 million in 2025 from $119.4 million in 2024, driven by advancement of the Phase 3 ARCHER II trial and regulatory filings for tanruprubart.
- Net loss attributable to common stockholders was $208.5 million in 2025, up from $138.2 million in 2024.
- Topline Phase 3 ARCHER II data for vonaprument in geographic atrophy (GA) expected in Q4 2026.
- Marketing Authorization Application (MAA) filed in Europe for tanruprubart in Guillain-Barré Syndrome (GBS); U.S. BLA submission anticipated in 2026.
Financial Impact
Increased R&D spending by $65.3 million YoY to $184.7 million; net loss widened to $208.5 million in 2025 from $138.2 million in 2024.
Risk Factors
- Clinical trial results may not meet endpoints, particularly the primary endpoint of visual acuity preservation in the ARCHER II trial.
- Regulatory delays or rejections for tanruprubart in Europe or the U.S. could negatively impact valuation.
- Cash runway extends into H2 2027, but additional financing may be required depending on development timelines and commercialization plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264990 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 10w ago | ANALYST-UPGRADE | $5.26 $5.18 | ▼ −1.52% | ▲ +0.44% | $3.69 (−29.75%) |
Aug 12, 2026 10w ago | 8-K | $5.33 $5.50 | ▲ +3.19% | ▲ +3.63% | $3.69 (−30.68%) |
Aug 12, 2026 10w ago | Press Release | $5.33 $5.50 | ▲ +3.19% | ▲ +3.63% | $3.69 (−30.68%) |
Aug 10, 2026 11w ago | 8-K | $5.34 $5.28 | ▼ −1.12% | ▼ −0.72% | $3.69 (−30.81%) |
Aug 7, 2026 11w ago | Institutional Cluster | $5.41 $5.29 | ▼ −2.22% | ▼ −2.62% | $3.69 (−31.70%) |
Aug 6, 2026 11w ago | Press Release | $5.60 $5.26 | ▼ −6.07% | ▼ −7.28% | $3.69 (−34.02%) |
Jul 21, 2026 14w ago | ANALYST-UPGRADE | $5.39 $5.13 | ▼ −4.82% | ▼ −3.60% | $3.69 (−31.45%) |
Jul 14, 2026 15w ago | 144 | $5.55 $5.57 | ▲ +0.36% | ▲ +1.66% | $3.69 (−33.42%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.70 $4.94 | ▲ +5.11% | ▲ +4.67% | $3.69 (−21.38%) |
May 12, 2026 24w ago | ANALYST-UPGRADE | $5.44 $4.96 | ▲ +8.82% | ▲ +8.90% | $3.69 (+32.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers